Risk of melanoma and nonmelanoma skin cancer with immunosuppressants Part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors

In solid organ transplant recipients, skin cancer risk associated with post-transplant immunosuppression has been well-described, and screening practices generally reflect these risks. In addition to agents used post-transplant, other classes of immunosuppressants also have the potential to raise the risk of nonmelanoma skin cancer (NMSC) or melanoma. In the present manuscript, the evidence for melanoma and NMSC risk associated with methotrexate, cyclophosphamide, biologic cytokine inhibitors including TNF-alpha and interleukin inhibitors, costimulation blockers such as abatacept, integrin inhibitors such as natalizumab, targeted B-cell and T-cell inhibitors including CD20, CD52, and BTK inhibitors, and JAK inhibitors is reviewed.

Source: Journal of the American Academy of Dermatology - November 29, 2022 Category: Dermatology Authors: Margaret Ann Kreher, Sailesh Konda, Mary Margaret B. Noland, Maria I. Longo, Rodrigo Valdes-Rodriguez Source Type: research